A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03288480
• Other study ID #: PT-112-102
• Status: Completed
• Phase: Phase 1
• Start date: December 15, 2017
• Est. completion date: March 1, 2021

Study information

• Verified date: April 2022
• Source: Phosplatin Therapeutics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study PT-112-102, a multicenter, open-label dose-finding and pharmacokinetic study of PT-112 in patients with relapsed or refractory multiple myeloma.

This is designed as a two-part study. In the first part of the study, cohorts of three patients (expanded to six patients in the event of a dose-limiting toxicity) will receive escalating doses of PT-112 until the MTD is reached, based on tolerability observed during the first 28 days of treatment. In the second part of the study, an expansion cohort of 14 patients will be treated at the recommended dose to confirm the tolerability of treatment and evaluate evidence of treatment efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: March 1, 2021
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

1. Previously diagnosed with MM requiring treatment based on IMWG diagnostic criteria;

2. Relapsed or refractory MM after adequate exposure to and therapeutic response (following IMWG response criteria) to at least one line of treatment with one or more active agents, including alkylating drugs, corticosteroids, immunomodulatory drugs (IMiD: thalidomide, lenalidomide, pomalidomide), proteasome inhibitors (bortezomib, cartilzomib), and monoclonal antibodies (daratumumab, elotuzumab, ixazomab);

3. Evaluable MM with at least one of the following: (a) serum monoclonal component = 0.5 g/dL; or (b) Bence Jones (BJ) proteinuria = 200 mg/24h; or (c) measurable plasmacytoma (not previously irradiated); or (d) involved serum free light chain = 10 mg/dL with an abnormal free light chain ratio;

4. ECOG Performance Status (PS) 0-2;

5. Life expectancy > 3 months;

6. At least 2 weeks (or 5 half-lives, whichever is longer) wash-out since the end of previously administered experimental therapy (6 weeks if previous nitrosourea containing regimen) or 2 weeks for standard-of-care regimens. Concurrent corticosteroids are allowed provided they are administered at an equivalent prednisone dose of = 10 mg/day, as prediction or blood products only;

7. Recovery from non-hematologic toxic effects of prior therapy to grade = 1 (except alopecia) by NCI CTCAE Version 4.03;

8. Adequate bone marrow (BM), renal, hepatic and metabolic function.

Key Exclusion Criteria:

1. Any of the following concomitant diseases/conditions:

• History or presence of myocardial infarction, clinically relevant valvular heart disease, or congestive heart failure within the last 12 months;

• Unstable cardiac dysrhythmias or persistent prolongation of the corrected QT interval (QTc) (Fridericia) to >480 msec for males or >500 msec for females, based on ECG at screening (patients with stable atrial fibrillation on treatment are allowed provided they do not meet any other cardiac or prohibited drug exclusion criterion);

• Presence of current angina;

• Active uncontrolled infection;

• Morphological or cytological features of myelodysplasia and/or post-chemotherapy aplasia on BM assessment;

• Myopathy > grade 2 or any clinical situation that causes significant and persistent elevation of CPK (>2.5 x ULN in two different determinations performed one week apart);

• Peripheral neuropathy > grade 1, except for grade 2 without limitations on instrumental daily life activities;

• POEMS syndrome or active plasma cell leukemia;

• Chronic graft versus host disease (GVHD) or on immunosuppressive therapy for the control of GVHD;

• History or presence within the last 3 months of Deep Vein Thrombosis (DVT) or a pulmonary embolism (PE);- Uncontrolled leptomeningeal disease;

• Uncontrolled disease-related metabolic disorder (e.g., hypercalcemia);

• Acute or chronic infections requiring systemic therapy, including, among others:

• active infection requiring systemic therapy;

• history of testing positive to human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome;

• hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test is positive);

• active tuberculosis (history of exposure or history of positive TB test with presence of clinical symptoms, physical or radiographic finding);

• Any other major illness that, in the Investigator's judgment, may substantially increase the risk associated with the patient's participation in this study;

2. History of prior malignancy other than those previously treated with a curative intent more than 5 years ago and without relapse (any tumor) or basal cell skin cancer, in situ cervical cancer, superficial bladder cancer, or high grade intestinal polyps treated adequately, regardless of the disease-free interval;

3. Prior irradiation to > 30% of BM reserves (including total body irradiation), regardless of the washout period;

4. High dose chemotherapy followed by autologous stem cell transplantation within 90 days prior to initiating study treatment;

5. Bisphosphonate treatment within 7 days prior to initiating study treatment (while on study, bisphosphonates can be administered only once a month, between Days 18 to 21 of the 28-day treatment cycle)

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• PT-112
This is a single arm study

Locations

Country	Name	City	State
United States	Rocky Mountain Cancer Centers	Denver	Colorado
United States	Mayo Clinic Cancer Center	Jacksonville	Florida
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Mayo Clinic Cancer Center	Phoenix	Arizona
United States	Mayo Clinic Cancer Center	Rochester	Minnesota
United States	Texas Oncology San Antonio Medical Center	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Phosplatin Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recommended dose (RD) of PT-112 for further studies in patients with relapsed or refractory multiple myeloma (MM)		18 months
Secondary	Peak Plasma Concentration (Cmax)		18 months
Secondary	Area under the plasma concentration versus time curve (AUC)		18 months
Secondary	Dose-limiting toxicities (DLTs)		18 months
Secondary	Number of patients with Adverse Events (AEs)	Characterization of the type, incidence, severity, duration, reversibility and relationship to treatment of adverse events (AEs), and effects on vital signs and laboratory parameters.	18 months
Secondary	Tumor response, including assessment of minimal residual disease, according to the International Myeloma Working Group (IMWG) response criteria		18 months
Secondary	Duration of response		18 months
Secondary	Progression free survival		18 months
Secondary	Relationship between sensitivity/response to treatment and disease status including cytogenetic biomarkers		18 months